Molecular and Cellular Biochemistry

, Volume 266, Issue 1–2, pp 57–63 | Cite as

Aspirin-induced apoptosis in Jurkat cells is not mediated by peroxisome proliferator-activated receptor delta

  • José M. López
  • Manuel A. Fernández
  • Maria Piqué
  • Joan Gil


Nonsteroidal antiinflammatory drugs may induce apoptosis via inhibition of peroxisome proliferator-activated receptor delta (PPARδ) activity. Here we analyze the role of PPARδ in aspirin-induced apoptosis of Jurkat cells, which, together with other lymphoid cell lines, express PPARδ mRNA. Aspirin increased PPARδ mRNA levels in Jurkat cells, but decreased the activity of both PPARδ and PPARα/γ, assayed using the luciferase reporter constructs DRE and ACO, respectively. The DNA binding of PPARδ was not affected by 10 mM aspirin, which induces apoptosis in Jurkat cells. Moreover, neither addition of a specific ligand of PPARδ nor transient transfection of PPARδ expression vectors protected Jurkat cells from aspirin-induced apoptosis. These results indicate that PPARδ is not involved in aspirin-induced apoptosis. Therefore, the mechanism by which aspirin mediates cell death in Jurkat cells remains unknown (Mol Cell Biochem 266: 57–63, 2004)

apoptosis aspirin Jurkat lymphoid cells NSAIDs PPAR 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lauer MS: Clinical practice. Aspirin for primary prevention of coronary events. N Engl J Med 346: 1468–1474, 2002Google Scholar
  2. 2.
    Huls G, Koorstra JJ, Kleibeuker, JH: Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. Lancet 362: 230–232, 2003Google Scholar
  3. 3.
    Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38: 97–120, 1998.Google Scholar
  4. 4.
    Shiff SJ, Rigas B: Nonsteroidal anti-inflammatory drugs and colorectal cancer: Evolving concepts of their chemopreventive actions. Gastroenterology 113: 1992–1998, 1997Google Scholar
  5. 5.
    Tegeder I, Pfeilschifter J, Geisslinger G: Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 15: 2057–2072, 2001Google Scholar
  6. 6.
    Chan, TA: Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 3: 166–174, 2002Google Scholar
  7. 7.
    Castaño E, Dalmau M, Barragán M, Pueyo G, Bartrons R, Gil J: Aspirin induces cell death and caspase-dependent phosphatidylserine externalization in HT-29 human colon adenocarcinoma cells. Br J Cancer 81: 294–299, 1999Google Scholar
  8. 8.
    Bellosillo B, Piqué M, Barragán M, Castaño E, Villamor N, Colomer D, Montserrat E, Pons G, Gil J: Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells. Blood 92: 1406–1414, 1998Google Scholar
  9. 9.
    Piqué M, Barragán M, Dalmau M, Bellosillo B, Pons G, Gil J: Aspirin induces apoptosis through mitochondrial cytochrome c release. FEBS Lett 480: 193–196, 2000Google Scholar
  10. 10.
    Yamamoto Y, Yin MJ, Lin KM, Gaynor RB: Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 274: 27307–27314, 1999Google Scholar
  11. 11.
    Liptay S, Bachem M, Hacker G, Adler G, Debatin KM, Schmid RM: Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine. Br J Pharmacol 128: 1361–1369, 1999Google Scholar
  12. 12.
    Stark LA, Din FV, Zwacka RM, Dunlop MG:Aspirin-induced activation of the NF-kappaB signaling pathway: A novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J 15: 1273–1275, 2001Google Scholar
  13. 13.
    Spiegelman BM, Flier JS: Adipogenesis and obesity: Rounding out the big picture. Cell 87: 377–389, 1996Google Scholar
  14. 14.
    Van Bilsen M, Van der Vusse GJ, Gilde AJ, Lindhout M, Van der Lee KAJM: Peroxisome proliferator-activated receptors: Lipid binding proteins controlling gene expression. Mol Cell Biochem 239: 131–138, 2002Google Scholar
  15. 15.
    Delerive P, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol 169: 453–459, 2001Google Scholar
  16. 16.
    Kersten S, Desvergne B, Wahli W: Roles of PPARs in health and disease. Nature 405: 421–424, 2000Google Scholar
  17. 17.
    He T-C, Chan TA, Vogelstein B, Kinzler KW: PPAδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99: 335–345, 1999Google Scholar
  18. 18.
    Gupta RA, Tan J, Krause WF, Geraci MW, Willson TM, Dey SK, DuBois RN: Prostacyclin-mediated activation of peroxisome proliferator-activated receptor β in colorectal cancer. Proc Natl Acad Sci USA 97: 13275–13280, 2000Google Scholar
  19. 19.
    Tong BJ, Tan J, Tajeda L, Das SK, Chapman JA, DuBois RN, Dey SK: Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia 2: 483–490, 2000Google Scholar
  20. 20.
    Hatae T, Wada M, Yokoyama C, Shimonishi M, Tanabe T: Prostacyclin-dependent apoptosis mediated by PPAR delta. J Biol Chem 276: 46260–46267, 2001Google Scholar
  21. 21.
    Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM: Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 91: 7355–7359, 1994Google Scholar
  22. 22.
    Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, Rodan GA: Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol Endocrinol 6: 1634–1641, 1992Google Scholar
  23. 23.
    Skogsberg J, Kannisto K, Roshani L, Gagne E, Hamsten A, Larsson C, Ehrenborg E: Characterization of the human peroxisome proliferator activated receptor delta gene and its expression. Int J Mol Med 6: 73–81, 2000Google Scholar
  24. 24.
    Kwon G, Hill JR, Corbett JA, McDaniel ML: Effects of aspirin on nitric oxide formation and de novo protein synthesis by RINm5F cells and rat islets. Mol Phamacol 52: 398–405, 1997Google Scholar
  25. 25.
    Iglesias-Serret D, Piqué M, Gil J, Pons G, López JM: Transcriptional and translational control of Mcl-1 during apoptosis. Arch Biochem Biophys 417: 141–152, 2003Google Scholar
  26. 26.
    Mascaró C, Acosta E, Ortiz JA, Marrero PF, Hegardt FG, Haro D: Control of human muscle-type carnitine palmitoyltransferase I gene tran-scription by peroxisome proliferator-activated receptor. J Biol Chem 273: 8560–8563, 1998Google Scholar
  27. 27.
    Forman BM, Chen J, Evans RM: Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 94: 4312–4317, 1997Google Scholar
  28. 28.
    Suchanek KM, May FJ, Lee WJ, Holman NA, Roberts-Thomson SJ: Peroxisome proliferator-activated receptor β expression in human breast epithelial cell lines of tumorigenic and non-tumorigenic origin. Int J Biochem Cell Biol 34: 1051–1058, 2002Google Scholar
  29. 29.
    Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272: 3406–3410, 1997Google Scholar
  30. 30.
    Park BH, Vogelstein B, Kinzler KW: Genetic disruption of PPAβ decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA 98: 2598–2603, 2001Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • José M. López
    • 1
    • 2
  • Manuel A. Fernández
    • 1
    • 3
  • Maria Piqué
    • 1
    • 2
  • Joan Gil
    • 1
  1. 1.Unitat de Bioquímica, Departament de Ciències Fisiològiques IIUniversitat de Barcelona, Campus de BellvitgeL'HospitaletSpain
  2. 2.Centre de Regulació GenòmicaPrograma d'Expressió Gènica, Pg. Maritim 37-49BarcelonaSpain.
  3. 3.Departament de Biologia Celular i Anatomia Patològica, Institut d' Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Facultat de MedicinaUniversitat de BarcelonaBarcelonaSpain

Personalised recommendations